Operationalizing the 2025 AHA/ACC hypertension guideline: PREVENT calculator and the dementia link
Industry Buzz
If the brain cannot properly clear toxins and metabolic byproducts, they will accumulate and may contribute to the development of dementia.
—Kyle Kern, MD
For many primary care physicians, the 2025 American Heart Association (AHA)/American College of Cardiology (ACC) hypertension guidelines will feel familiar at first glance. []
The diagnostic threshold did not move: Hypertension still starts at 130/80 mm Hg. Stage I still means systolic pressure of 130–139 mm Hg or diastolic pressure of 80–89 mm Hg. Stage II still begins at 140/90 mm Hg. []
What has changed is the clinical frame around those numbers. The new guideline asks clinicians to move beyond “Is this blood pressure high enough to treat?” and toward “What does this blood pressure mean for this patient’s cardiovascular, kidney, metabolic, and cognitive risk over time?”
That shift matters in a busy clinic, especially for primary care physicians managing patients who may be younger, asymptomatic, and skeptical that a blood pressure of 132/84 deserves more than a shrug. The practical answer is PREVENT.
PREVENT gives Stage I hypertension a risk conversation
The PREVENT calculator—short for Predicting Risk of Cardiovascular Disease EVENTs—was developed by the AHA to estimate 10- and 30-year risk of cardiovascular disease. []
Unlike the older pooled cohort equations, PREVENT incorporates the modern cardiovascular-kidney-metabolic picture: blood pressure, cholesterol, diabetes, smoking status, body mass index, kidney function, and optional inputs such as urine albumin-creatinine ratio, hemoglobin A1c, and social deprivation index. []
That makes it especially useful for the patient sitting in front of you whose risk is not fully captured by a blood pressure category alone.
The 2025 guideline recommends using PREVENT-CVD to guide management for adults with Stage I hypertension who do not already have cardiovascular disease, diabetes, or chronic kidney disease. []
In that group, a 10-year PREVENT-CVD risk of 7.5% or higher supports starting antihypertensive therapy. If the patient’s 10-year risk is below 7.5%, lifestyle therapy remains the initial move—but the guideline gives a clear next step: if average blood pressure remains at or above 130/80 mm Hg after 3 to 6 months, medication is recommended. []
That is a subtle but important operational change. Stage I hypertension is no longer a gray zone where clinicians can indefinitely repeat “diet and exercise” without a defined follow-up plan. PREVENT helps clinicians decide who needs medication now, who gets a lifestyle-first trial, and when that trial should be reassessed.
Related: Are we getting blood pressure all wrong? A healthcare reality checkThe tighter target is about cumulative exposure
The guideline’s overall treatment goal remains less than 130/80 mm Hg for most adults with hypertension. But its message pushes clinicians to think earlier and more aggressively about cumulative vascular exposure, with intensive control moving patients closer to 120/80 mm Hg when it can be achieved safely and tolerably.
That does not mean every patient needs a sprint to systolic 120. It does mean that a blood pressure of 138/86 in a 42-year-old should not be treated as “mild” simply because the patient is young. Younger patients may have lower 10-year event risk, but they often have decades of exposure ahead. PREVENT’s 30-year estimates can make that visible.
This is where shared decision-making becomes more concrete. Instead of saying, “Your blood pressure is a little high,” a clinician can say, “Your current numbers put you in Stage I hypertension. Your 10-year risk is below the medication threshold today, but your 30-year risk is meaningful. Let’s take 3 months to work on sodium, activity, weight, sleep, alcohol, and home readings. If your average is still 130/80 or higher, we should start medication.”
That conversation is clearer, less paternalistic, and easier to document.
The dementia link changes the stakes
The 2025 guidelines also elevate an outcome that patients increasingly care about: brain health. Hypertension has long been framed around myocardial infarction, stroke, heart failure, and chronic kidney disease.
Those remain central. But the guideline emphasizes that blood pressure also affects cognitive function and dementia risk, likely through vascular injury, small-vessel disease, and long-term effects on cerebral perfusion and brain structure. []
“If the brain cannot properly clear toxins and metabolic byproducts, they will accumulate and may contribute to the development of dementia,” said neurologist Kyle Kern, MD. []
For patients, this can be a more motivating conversation than abstract cardiovascular risk. Many patients who are ambivalent about preventing a future cardiac event are highly motivated to preserve memory, independence, and executive function.
For clinicians, the dementia link is a reminder that “asymptomatic” hypertension is not benign hypertension. The damage is often silent until it is not. Brain health gives PCPs another clinically honest reason to treat earlier, monitor more consistently, and avoid therapeutic inertia.
How to make PREVENT clinic-ready
The challenge is not whether PREVENT is useful. The challenge is how to use it without turning a 15-minute visit into a risk-modeling exercise.
A practical workflow can be simple.
Confirm the blood pressure. Use the correct cuff size, repeat the measurement, and ask for home or ambulatory readings when office values are uncertain.
Classify the patient. Normal, elevated, Stage I, or Stage II still matters. Stage II hypertension generally warrants medication regardless of PREVENT risk. Stage I hypertension is where PREVENT adds the most decision support.
Identify automatic high-risk groups. Patients with established cardiovascular disease, diabetes, or chronic kidney disease often already meet treatment indications. PREVENT is most helpful for Stage I patients without those conditions.
Run PREVENT-CVD using the best available data. In many patients, you will already have the basics: age, sex, systolic blood pressure, lipids, smoking status, diabetes status, antihypertensive use, statin use, BMI, and eGFR.
Translate the result into a plain-language plan. A PREVENT-CVD risk of 7.5% or higher in Stage I hypertension supports starting medication. A result below 7.5% supports lifestyle therapy first, followed by reassessment in 3 to 6 months. Persistent average blood pressure at or above 130/80 mm Hg should trigger medication rather than another open-ended lifestyle reminder.
If urine albumin-creatinine ratio and A1c are clinically indicated or available, add them. The 2025 guideline also recommends urine albumin-creatinine ratio for all patients with hypertension, which should make PREVENT more informative over time.
Related: New research: High BP quietly ages the brain—decades before dementiaWhat this means for PCPs
Younger physicians entered practice in an era of shared decision-making, quality metrics, digital tools, and patients who often arrive with smartwatch data, home cuff readings, and strong preferences about medication. The 2025 guideline fits that environment.
PREVENT is a way to make the blood pressure conversation more individualized without making it vague. It can show why two patients with the same 134/82 reading may require different levels of urgency.
It can also help explain why a patient with “only Stage I” hypertension may still benefit from medication if their kidney, metabolic, or heart failure risk is elevated.
The key is to avoid using PREVENT as a black box. The calculator should support the conversation, not replace clinical judgment. Frailty, orthostatic symptoms, pregnancy considerations, medication burden, cost, adherence, and patient goals still matter. So does the quality of the blood pressure measurement itself.